Meropenem
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| BROOKS STERISCIENCE LIMITED | unknown | 7 | SUPPLYING |
| Armas Pharmaceuticals Inc. | unknown | 6 | SUPPLYING |
| Sandoz Inc | generic | 4 | SUPPLYING |
| Civica, Inc | unknown | 4 | SUPPLYING |
| Qilu Antibiotics Pharmaceutical Co., Ltd. | unknown | 2 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | generic | 2 | SUPPLYING |
| Savior Lifetec Corporation | unknown | 2 | SUPPLYING |
| Gland Pharma Limited | generic | 2 | SUPPLYING |
| Mylan Institutional LLC | unknown | 1 | SUPPLYING |
No recalls, shortages, or registration changes on record for this drug concept.
